Anne‐Charlotte Le Monnier de Gouville
GlaxoSmithKline (United Kingdom)(GB)GlaxoSmithKline (France)(FR)
Publications by Year
Research Areas
Nitric Oxide and Endothelin Effects, Phosphodiesterase function and regulation, Renin-Angiotensin System Studies, Receptor Mechanisms and Signaling, Cardiac electrophysiology and arrhythmias
Most-Cited Works
- → The Discovery of Tadalafil: A Novel and Highly Selective PDE5 Inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1‘,2‘:1,6]pyrido[3,4-b]indole-1,4-dione Analogues(2003)279 cited
- → The Discovery of Tadalafil: A Novel and Highly Selective PDE5 Inhibitor. 1: 5,6,11,11a-Tetrahydro-1H-imidazo[1‘,5‘:1,6]pyrido[3,4-b]indole-1,3(2H)-dione Analogues(2003)192 cited
- → Endothelin - a new family of endothelium-derived peptides with widespread biological properties(1989)92 cited
- → Effects of cyclic GMP elevation on isoprenaline‐induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3(1996)87 cited
- → Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats(1998)24 cited
- → Cross tachyphylaxis to endothelin isopeptide‐induced hypotension: a phenomenon not seen with proendothelin(1991)23 cited
- → GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial(2015)19 cited
- → Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization(1996)17 cited
- → Differential Pharmacological Profile of Endothelin-1 and Its Precursor, Big Endothelin(1991)5 cited